Trastuzumab-induced toxic epidermal necrolysis in a Her-2-positive metastatic breast cancer patient-A rare case report

被引:0
|
作者
Ferdause, Jannatul [1 ]
Momtahena, Sura Jukrup [1 ]
Karim, Rubama [1 ]
Chowdhury, Aditi Paul [1 ]
Hossain, Nowshin Taslima [1 ]
Islam, Md Ariful [1 ]
Bin Habib, Maruf [2 ]
Kadir, A. K. M. Shafiul [3 ]
Haque, Md Ariful [4 ,5 ,6 ]
机构
[1] Ahsania Mission Canc & Gen Hosp, Dhaka, Bangladesh
[2] Ahsania Mission Med Coll, Dept Med, Dhaka, Bangladesh
[3] Quest Bangladesh Biomed Res Ctr, Dhaka, Bangladesh
[4] Atish Dipankar Univ Sci & Technol, Dept Publ Hlth, Dhaka, Bangladesh
[5] Voice Doctors Res Sch, Dhaka, Bangladesh
[6] Kunming Med Univ, Yanan Hosp, Dept Orthopaed Surg, Kunming, Yunnan, Peoples R China
来源
CLINICAL CASE REPORTS | 2024年 / 12卷 / 07期
关键词
anti HER-2 antibody; HER-2-positive breast cancer; Steven Johnson syndrome; toxic epidermal necrolysis; Trastuzumab; STEVENS-JOHNSON SYNDROME; GUIDELINES; MANAGEMENT; COMPLICATIONS; INVOLVEMENT;
D O I
10.1002/ccr3.9103
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Toxic Epidermal Necrolysis (TEN) is a rare, but potentially fatal mucocutaneous reaction, that may occur due to an immunologic response to certain medications. However, TEN triggered by Trastuzumab is extremely rare. Early diagnosis, recognition, and prompt cessation of the offending drugs and initiation of steroid therapy with supportive management are the most important actions for managing TEN. Although rare, it is important to be vigilant about this potential adverse reactions associated with trastuzumab to ensure patient safety and contribute to better outcomes.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Risk Factors Associated with Trastuzumab-induced Cardiotoxicity in Patients with Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
    Abdel-Razaq, Wesam
    Alzahrani, Mohammed
    Al Yami, Majed
    Almugibl, Faisal
    Almotham, Mohammed
    Alregaibah, Razan
    JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2019, 11 (04): : 348 - 354
  • [42] Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer
    Martin, Miguel
    Makhson, Anatoly
    Gligorov, Joseph
    Lichinitser, Mikhail
    Lluch, Ana
    Semiglazov, Vladimir
    Scotto, Nana
    Mitchell, Lada
    Tjulandin, Sergei
    ONCOLOGIST, 2012, 17 (04) : 469 - 475
  • [43] Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells
    Browne, B. C.
    Crown, J.
    Venkatesan, N.
    Duffy, M. J.
    Clynes, M.
    Slamon, D.
    O'Donovan, N.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 68 - 73
  • [44] Gefitinib-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Non-small cell Lung Cancer
    Yang, L.
    Lam, K. O.
    Lee, V. H. F.
    Lee, A. W. M.
    HONG KONG JOURNAL OF RADIOLOGY, 2018, 21 (02): : E8 - E11
  • [45] Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature
    Isabel Ihnenfeld Arciénega
    Patrick Imesch
    Daniel Fink
    Konstantin J. Dedes
    Targeted Oncology, 2015, 10 : 297 - 301
  • [46] Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
    Steenbruggen, T. G.
    Bouwer, N. I.
    Smorenburg, C. H.
    Rier, H. N.
    Jager, A.
    Beelen, K.
    ten Tije, A. J.
    de Jong, P. C.
    Drooger, J. C.
    Holterhues, C.
    Kitzen, J. J. E. M.
    Levin, M-D.
    Sonke, G. S.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 178 (03) : 597 - 605
  • [47] Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature
    Arcienega, Isabel Ihnenfeld
    Imesch, Patrick
    Fink, Daniel
    Dedes, Konstantin J.
    TARGETED ONCOLOGY, 2015, 10 (02) : 297 - 301
  • [48] The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review
    Tokuda, Yutaka
    Suzuki, Yasuhiro
    Saito, Yuki
    Umemura, Shinobu
    BREAST CANCER, 2009, 16 (04) : 295 - 300
  • [49] Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
    Mateus de Oliveira Taveira
    Sheida Nabavi
    Yuker Wang
    Peter Tonellato
    Francisco J. Esteva
    Lewis C. Cantley
    Gerburg M. Wulf
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 1255 - 1262
  • [50] Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
    Taveira, Mateus de Oliveira
    Nabavi, Sheida
    Wang, Yuker
    Tonellato, Peter
    Esteva, Francisco J.
    Cantley, Lewis C.
    Wulf, Gerburg M.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (07) : 1255 - 1262